Nevakar Completes Enrollment for its Phase III CHAMP Study of NVK-002

Published: 11/09/2019
Nevakar Completes Enrollment for its Phase III CHAMP Study of NVK-002
Source: WWW.PRNEWSWIRE.COM

BRIDGEWATER, N.J., Sept. 11, 2019 /PRNewswire/ -- Nevakar Inc., a privately-held, late-stage specialty pharmaceutical company dedicated to developing innovative ophthalmic products, announced today that it has completed enrollment for its Phase III CHAMP (Childhood Atropine for Myopia...

Read more
Related news
Comment
FACEBOOK